5'-N-Ethylcarboxamidoadenosine NEW
| Price | $41 | $51 | $97 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: 5'-N-Ethylcarboxamidoadenosine | CAS No.: 35920-39-9 |
| Purity: ≥95% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | 5'-N-Ethylcarboxamidoadenosine |
| Description | 5'-N-Ethylcarboxamidoadenosine (NECA), an agonist of the Adenosine receptor, increases cerebral extravasation of fluorescein and low molecular weight dextran independent of blood-brain barrier modulation. |
| Cell Research | A human hepatocellular carcinoma cell line (Hep3B) was employed to determine the in vitro effects of NECA on Epo production and cAMP accumulation. Hep3B cells were carried in a monolayer cell culture and maintained in 75 cm^2 Corning culture flasks containing Eagle's minimal essential medium (MEM) supplemented with 10% fetal bovine serum (PBS), 0.1 m nonessential amino acids, 1 m sodium pyruvate, 100 U/ml penicillin G, and 100 μg/ml streptomycin in a humidified atmosphere of 5% C02/95% air at 37℃. The culture medium was replaced every two days. Cells were detached with trypsin and aliquots of 2.5 x 10^5 viable cells (determined by trypan blue dye exclusion) were transferred to 24 multi-well plates. Each experiment was carried out with low density cells before they reached confluency. The cells were incubated with NECA in concentrations of 1O^9 M to 5 x l0^-5 M in the presence of 1 U/ml adenosine deaminase (ADA) under hypoxic conditions (1% 02, 5% C02, and 94% N2) for 20 hours following 24 hour preincubation in a normoxic atmosphere. At the end of the incubation period, the supernatant was harvested and frozen at -70℃ prior to Epo RIA. The multiple-range test of Duncan was used for the comparison of the several in vitro treatment groups compared with controls[1]. |
| In vitro | In vitro cultures of an Epo producing hepatocellular carcinoma (Hep3B) cell line with 5'-N-Ethylcarboxamidoadenosine (> or = 10(-6) M) for 20 hours under hypoxic conditions (1% O2) produced significant increases in medium levels of Epo when compared with hypoxia controls. Hepatocellular carcinoma cells treated with 5'-N-Ethylcarboxamidoadenosine at a concentration range of 10(-7) M to 5 x 10(-5) M for one hour in a hypoxic atmosphere also had significantly higher cAMP levels than that of hypoxia controls. Scatchard analyses of [3H]5'-N-Ethylcarboxamidoadenosine binding to membrane preparations of hepatocellular carcinoma cells showed low affinity binding sites with a dissociation-constant (Kd) of 0.44 microM and a binding capacity of 863 fmol/mg protein. Suggest that the increase in Epo production in response to 5'-N-Ethylcarboxamidoadenosine under hypoxic conditions can be attributed, at least in part, to stimulation of adenosine A2 receptors which is coupled to adenylyl cyclase activation[1]. |
| In vivo | 5'-N-Ethylcarboxamidoadenosine, an adenosine analogue, on erythropoietin (Epo) production. 5'-N-Ethylcarboxamidoadenosine (0.05 and 0.1 mumol/kg i.v.) produced significant increases in serum Epo levels (368.8 +/- 56.1 and 384.6 +/- 45.9 mU/ml, respectively) in exhypoxic polycythemic mice after a four hour exposure to hypoxia when compared with hypoxia controls (133.2 +/- 18.2 mU/ml). The hypoxic kidney Epo levels were 46.4 +/- 13.4 mU/kg kidney which were significantly higher than normoxic kidney Ep levels (< 1.24 mU/kg kidney). Theophylline (20 mg/kg i.p.), an adenosine receptor antagonist, significantly inhibited the stimulatory effects of 5'-N-Ethylcarboxamidoadenosine on serum Epo levels[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 150 mg/mL (486.55 mM) |
| Keywords | Adenosine Receptor | Inhibitor | 5'-N-Ethylcarboxamidoadenosine | inhibit | P1 receptor | 5' N Ethylcarboxamidoadenosine | 5'NEthylcarboxamidoadenosine |
| Inhibitors Related | Theobromine | Theophylline | Doxofylline |
| Related Compound Libraries | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Anti-Viral Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Human Metabolite Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/5mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $0.00/1KG |
VIP4Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2023-01-13 | |
| $79.00/1kg |
VIP1Y
|
Hebei Zhuanglai Chemical Trading Co Ltd
|
2024-11-25 | |
| $7.00/1KG |
VIP7Y
|
Career Henan Chemical Co
|
2019-09-01 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY